Luspatercept

Drug Profile

Luspatercept

Alternative Names: ACE-536

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation
  • Class Antianaemics; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Beta-thalassaemia; Myelodysplastic syndromes
  • Phase II Anaemia
  • Preclinical Sickle cell anaemia

Most Recent Events

  • 30 Jan 2017 Phase-III clinical trials in Myelodysplastic syndromes in Turkey (SC) (NCT02631070)
  • 09 Jan 2017 Acceleron Pharma plans a phase II trial for beta-thalassaemia
  • 09 Jan 2017 Acceleron Pharma plans a phase II trial for Myelofibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top